
Opinion|Videos|June 27, 2024
Best Candidates for HER2-Directed ADCs in HR+/HER2-Low Metastatic Breast Cancer
Author(s)Aditya Bardia, MD, MPH, Laura Huppert, MD
Experts on breast cancer describe the best candidates for HER2-directed antibody-drug conjugates in HR+/HER2-low metastatic breast cancer, highlighting the role of trastuzumab deruxtecan in later lines of therapy.
Advertisement
Episodes in this series

Video content above is prompted by the following questions:
- Which patients are most suitable for a HER2-directed antibody-drug conjugate (ADC) in HR+/HER2-low metastatic breast cancer?
- Would you consider trastuzumab deruxtecan for second-line therapy or as a later line?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Priority Review to Dato-DXd First-Line Metastatic TNBC
2
Managing Toxicity and Safety of Belzutifan in ccRCC
3
Spotlighting Sequencing and Biomarkers in Bladder Cancer Management
4
Dr Shubham Pant Highlights Progress and Promise in Pancreatic Cancer Treatment
5




















